Association Between Liver Fibrosis and Cause-Specific Mortality in Japanese Patients With Biopsy-Confirmed Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1109 patients, 1104 met the MASLD criteria.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
MASH may contribute to increased nonliver-related deaths. Further long-term studies are warranted.
[BACKGROUND] This study examined mortality patterns and their association with liver fibrosis in Japanese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD
- 표본수 (n) 17
- p-value p < 0.0001
- 추적기간 6.9 years
APA
Sakai K, Shima T, et al. (2026). Association Between Liver Fibrosis and Cause-Specific Mortality in Japanese Patients With Biopsy-Confirmed Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD.. Hepatology research : the official journal of the Japan Society of Hepatology, 56(1), 33-49. https://doi.org/10.1111/hepr.70034
MLA
Sakai K, et al.. "Association Between Liver Fibrosis and Cause-Specific Mortality in Japanese Patients With Biopsy-Confirmed Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD.." Hepatology research : the official journal of the Japan Society of Hepatology, vol. 56, no. 1, 2026, pp. 33-49.
PMID
40952893 ↗
Abstract 한글 요약
[BACKGROUND] This study examined mortality patterns and their association with liver fibrosis in Japanese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD).
[METHODS] We analyzed 1104 MASLD-eligible individuals from the Suita SLD cohort (2004-2023). Mortality rates were assessed using Kaplan-Meier analysis and compared between patients with and without fibrosis (Stages 1-4 vs. 0) and between metabolic dysfunction-associated steatohepatitis (MASH) and non-MASH groups, adjusting for age and sex. Associations between fibrosis or inflammation levels and cause-specific mortality were also evaluated.
[RESULTS] Of the initial 1109 patients, 1104 met the MASLD criteria. Among these patients (544 men, 560 women; mean age: 57.2 years; mean follow-up period: 6.9 years), 93 patients died, primarily from hepatocellular carcinoma (HCC) (n = 17), liver failure (n = 16), extrahepatic malignancies (n = 17), cardio-cerebrovascular diseases (n = 7), and other causes (n = 36). Fibrosis was associated with higher all-cause (11.4% vs. 3.6%) and liver-related mortality (4.8% vs. 0%, both p < 0.0001), but not with nonliver-related mortality after adjustment. All-cause mortality was higher in the MASH group (11.2% vs. 2.6%, p < 0.0001), with increased risk of both liver- and nonliver-related deaths (adjusted hazard ratios: liver-related = 1.34 × 10, 95% CI: NE, nonliver-related = 2.20, 95% confidence interval [CI]: 1.07-4.53).
[CONCLUSION] HCC and extrahepatic malignancies were the leading causes of death in Japanese patients with MASLD. Liver fibrosis was a significant predictor of both all-cause and liver-related mortalities, but not nonliver-related mortality, highlighting its importance in follow-up strategies for MASLD. MASH may contribute to increased nonliver-related deaths. Further long-term studies are warranted.
[METHODS] We analyzed 1104 MASLD-eligible individuals from the Suita SLD cohort (2004-2023). Mortality rates were assessed using Kaplan-Meier analysis and compared between patients with and without fibrosis (Stages 1-4 vs. 0) and between metabolic dysfunction-associated steatohepatitis (MASH) and non-MASH groups, adjusting for age and sex. Associations between fibrosis or inflammation levels and cause-specific mortality were also evaluated.
[RESULTS] Of the initial 1109 patients, 1104 met the MASLD criteria. Among these patients (544 men, 560 women; mean age: 57.2 years; mean follow-up period: 6.9 years), 93 patients died, primarily from hepatocellular carcinoma (HCC) (n = 17), liver failure (n = 16), extrahepatic malignancies (n = 17), cardio-cerebrovascular diseases (n = 7), and other causes (n = 36). Fibrosis was associated with higher all-cause (11.4% vs. 3.6%) and liver-related mortality (4.8% vs. 0%, both p < 0.0001), but not with nonliver-related mortality after adjustment. All-cause mortality was higher in the MASH group (11.2% vs. 2.6%, p < 0.0001), with increased risk of both liver- and nonliver-related deaths (adjusted hazard ratios: liver-related = 1.34 × 10, 95% CI: NE, nonliver-related = 2.20, 95% confidence interval [CI]: 1.07-4.53).
[CONCLUSION] HCC and extrahepatic malignancies were the leading causes of death in Japanese patients with MASLD. Liver fibrosis was a significant predictor of both all-cause and liver-related mortalities, but not nonliver-related mortality, highlighting its importance in follow-up strategies for MASLD. MASH may contribute to increased nonliver-related deaths. Further long-term studies are warranted.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- A feline case of intestinal small T-cell lymphoma with prominent lymphoid follicle formation and concurrent intestinal large B-cell lymphoma.
- Effectiveness of Educational Videos in Encouraging Preferences for Guideline-Based Cancer Screening in Japan: Three-Arm Pseudorandomized Controlled Trial.
- [Up-to-Date Chemotherapy for Endometrial Cancer].
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Correction: Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).
- Machine Learning-Based Prediction of Long-Term Mortality in STEMI Patients Using Clinical, Laboratory, and Inflammatory-Metabolic Indices.
- Are infertile men at a higher risk of morbidity and early mortality?
- Global, regional, and national analyses of the burden of pancreatic cancer attributable to high fasting plasma glucose from 1990 to 2021: A longitudinal observational study.
- Neighborhood obesogenic factors and breast cancer risk and mortality in the Southern community cohort study.
- Differences in utilization, complications, and mortality after cancer surgery by HIV status among Medicaid beneficiaries from 2001-2021.